Ameritas Investment Partners’s Tourmaline Bio TRML Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q4 | – | Sell |
-1,463
| Closed | -$70K | – | 3179 |
|
|
2025
Q3 | $70K | Sell |
1,463
-799
| -35% | -$22.2K | ﹤0.01% | 1904 |
|
|
2025
Q2 | $36.2K | Hold |
2,262
| – | – | ﹤0.01% | 2377 |
|
|
2025
Q1 | $34.4K | Hold |
2,262
| – | – | ﹤0.01% | 2308 |
|
|
2024
Q4 | $45.9K | Hold |
2,262
| – | – | ﹤0.01% | 2236 |
|
|
2024
Q3 | $58.2K | Hold |
2,262
| – | – | ﹤0.01% | 2098 |
|
|
2024
Q2 | $29.1K | Buy |
+2,262
| New | +$36.4K | ﹤0.01% | 2441 |
|
|
2023
Q2 | – | Sell |
-165
| Closed | -$3.1K | – | 3210 |
|
|
2023
Q1 | $3.1K | Hold |
165
| – | – | ﹤0.01% | 2930 |
|
|
2022
Q4 | $2.16K | Hold |
165
| – | – | ﹤0.01% | 3006 |
|
|
2022
Q3 | $4K | Hold |
165
| – | – | ﹤0.01% | 2956 |
|
|
2022
Q2 | $7K | Hold |
165
| – | – | ﹤0.01% | 2919 |
|
|
2022
Q1 | $16K | Hold |
165
| – | – | ﹤0.01% | 2653 |
|
|
2021
Q4 | $25K | Buy |
165
+95
| +136% | +$14.1K | ﹤0.01% | 2542 |
|
|
2021
Q3 | $9K | Hold |
70
| – | – | ﹤0.01% | 2971 |
|
|
2021
Q2 | $10K | Buy |
+70
| New | +$10.7K | ﹤0.01% | 2934 |
|
Ameritas Investment Partners's TRML Position: Q4 2025 in Review
Ameritas Investment Partners sold out of Tourmaline Bio (TRML) in Q4 2025, closing a stake of 1,463 shares — an estimated $70K sold.
Ameritas Investment Partners first reported a position in TRML in Q2 2021 and held it in 14 quarters. The position peaked at $70K in Q3 2025. 0 funds tracked by Wall St. Rank hold TRML as of Q4 2025.
- Ameritas Investment Partners reported no remaining Tourmaline Bio position as of Q4 2025 after selling out during the quarter.
- Ameritas Investment Partners sold 1,463 Tourmaline Bio shares in Q4 2025, an estimated $70K.
- Ameritas Investment Partners first reported a position in Tourmaline Bio in Q2 2021 and held it in 14 quarters.
- Ameritas Investment Partners's Tourmaline Bio position peaked at $70K in Q3 2025.
- 0 funds tracked by Wall St. Rank held Tourmaline Bio as of Q4 2025.
Based on Ameritas Investment Partners's 13F filing for Q4 2025, filed 11 Feb 2026.